EXHIBIT 26

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

Page 1

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

CHAPTER 11

IN RE:

W.R. GRACE & CO., et al.,

Debtors.

Case No. 01-1139(JFK)

Jointly Administered

DEPOSITION OF

Elizabeth L. Anderson, Ph.D.

November 2, 2007

Washington, D.C.

Lead: Walter B. Slocombe, Esquire

Firm: Caplin & Drysdale, Chartered

FINAL COPY

JANE ROSE REPORTING 1-800-825-3341

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 171
1	BY MR. SLOCOMBE:	
2	Q. What is the basis for saying that an	
3	individual's exposure in the category of being	
4	in the space where a Grace asbestos product was	
5	being mixed or installed will cluster toward the	
6	average?	
7	MS. HARDING: Object to form.	
8	THE WITNESS: Because the well,	
9	it's a it's a scientific fact that as you	
10	take long-term averages and assume that	
11	somebody is exposed for as long as the life of	
12	the product or 45 years, it's not just a day's	
13	exposure. And we have data to describe that	
14	average exposure. Over a very long period of	
15	time everybody is going to cluster toward that	
16	average.	
17	So it's scientifically supportable.	
18	But when we assume not that the person was	
.19	exposed one day or two days but the full	
20	lifetime of the product on the market or a	
21	45-year occupational exposure that the average	
22	exposure is going to well characterize what they	
23	were exposed to.	
24	BY MR. SLOCOMBE:	
25	Q. Did you look at the data that Dr. Lees	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 208
1	requirements associated with filling out the PIQ	
2	and other matters for that matter.	
3	MR. SLOCOMBE: Okay. I'll withdraw the	
4	question.	
5	BY MR. SLOCOMBE:	
6	Q. You've said that cases which were	
7	classified as insufficient information would be	
8	subject to further review.	
9	A. No, I didn't say that.	
10	Q. I'm sorry.	
11	What did you say with respect to	
12	further review about insufficient information	
13	cases?	
14	A. The purpose of this classification was	
15	not to try these cases and determine whether	
16	these claims should be made or not. This was a	
17	screening exercise.	
18	It was to set up an approach by which	
19	we could evaluate whether or not product groups	
20	or individuals even if we gave them 45 years of	
21	the highest possible exposure would have	
22	credible claims, and so then we could speak to	
23	the issue of screening claims that did not seem	
24	to be credible. Then we could talk about	
25	claims that might be credible and say those	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 209
1	would be subject to further case-by-case	
2	evaluation.	
3	This information was given to	
4	Dr. Florence and his team to use in their mixed	
5	analysis, and I don't know how they used it.	
6	But the point of this exercise is not	
7	to do a final trial but rather to provide an	
8	approach that allows us to make reasonable	
9	classifications of meritorious potentially	
10	meritorious claims versus those that have no	
11	scientific credibility.	
12	Q. Do I correctly understand that in the	
13	cases which were classified as insufficient	
14	information you were not necessarily determining	
15	that those cases had no scientific credibility,	
16	simply that there was not enough information to	
17	judge whether they did or not?	
18	MS. HARDING: Object to form. I think	
19	that	
20	THE WITNESS: It was as simple as	
21	saying they didn't provide sufficient	
22	information to be classified in one of these	
23	nature of exposure categories.	
24	BY MR. SLOCOMBE:	
25	O Vou've said and it cortainly seems to	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 245
1	how do you deal with data sets that you know are	
2	going to express the variability over long	
3	periods of time.	
4	And so I see no unique characteristics	
5	in this data set, and I'm not going to discuss	
6	Dr. Lees' data set any further because these are	
7	his data. He dealt with them. He knows the	!
8	background of these studies. And it's not	
9	appropriate for me to deal with his data sets in	
10	any more detail.	
11	BY MR. RASMUSSEN:	
12	Q. But one individual's exposure to	
13	asbestos could remain higher than the average	
14	exposure of the job category he was in for the	
15	course of his entire life; isn't that right?	
16	A. I don't think so.	
17	Q. Why not?	
18	A. Not because I have chosen to use	
19	these data sets over very, very long periods of	
20	time.	
21	And I think over long periods of time,	
22	in every guideline, in every application and all	
23	of EPA's guidance documents, you use the	
24	long-term averages. And that's exactly what	
25	I've done and I've assumed very, very long	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 246
1	periods, durations of exposure, the 45 years	
2	that the product that was on the market or the	
3	life of the product.	
4	And so I think that this is not a	
5	fruitful discussion.	
6	I mean, that's you have people	
7	averaging their exposures are going to	
8	average over these long durations, and so that's	
9	just not a correct portrayal.	
10	Q. Is it your testimony that all workers'	
11	exposure converged to the same identical mean	
12	value over the course of years?	
13	MS. HARDING: Object to form, and it	
14	mischaracterizes testimony.	
15	THE WITNESS: I've said I think this is	
16	a reasonable representation of the exposure over	
17	long durations.	
18	BY MR. RASMUSSEN:	
19	Q. For an individual?	
20	A. For anyone in these categories, because	
21	the data converge. And this is the way data	
22	sets are handled routinely across all of EPA's	
23	guidance, for air, for Superfund sites, for	
24	everything.	
25	O Is the convergence monotonic?	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 249
1	the wind blows one way, another way. There are	
2	different activities going on.	
3	And so what you want to capture over a	
4	long period of time for exposures that are very	
5	important to lifetime exposure circumstances is	
6	a fair characterization of all of this	
7	difference that you observe in the data sets.	
8	I've said, number two, that EPA has	
9	guidelines and practices that are documented for	
10	dealing with this. It's expected. This isn't	
11	unusual. It's expected. What these guidelines	
12	drive toward is a way of describing the best	
13	characteristics of the data set for long-term	
14	exposures.	
15	Number three, what we've done is we've	
16	applied those long-term these concentrations	
17	to long-term durations that are the longest that	
18	could possibly exist, either 45 years of	
19	employment or the full lifetime of the product.	
20	Therefore, I think these eight-hour averages are	
21	very representative of exposure across the	
22	universe of these individuals.	
23	I don't think that any individual for	
24	45 years is going to be exposed to one of the	
25	highest data points in this data set, and I	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

Page 283 1 for different application situations and different individuals therefore who would have 2 been in those particular environments, and he's 3 4 provided that. 5 And I've said that I think by selecting the highest of his averaged values and by 6 7 selecting the longest possible durations and by assuming that all the products that were used 8 9 were all Grace products and by assuming any 10 number of other very high-end assumptions, including my table 5 which assumes that anybody 11 12 could have been exposed to all of the Grace 13 products at the very highest level for 45 years, is a fair representation of the reasonable 14 high-end exposure that anybody could have 15 16 gotten. 17 So I don't think that you can separate exposures for sick people from not sick people 18 as far as Grace products are concerned for a 19 variety of reasons. Some people get sick and 20 21 some don't when they're exposed to the same 22 thing. 23 In your population of sick people, they 24 could have been exposed to any number of other 25 things and not just Grace products and for any

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 284
1	number of other reasons. Your question is not a	
2	question that has any other reasonable response	
3	than what I have given I don't think. I'm	
4	trying to be responsive, but I don't think I can	:
5	be more responsive.	
6	BY MR. RASMUSSEN:	
7	Q. If a claimant who has meso has a	
8	cumulative exposure level of 8 fiber per	
9	milliliter years from Grace products and an	
10	exposure of 8 fibers	
11	A. How many fibers?	
12	Q 8 from Grace and an exposure of	
13	8 fibers per millimeter year cumulative from	
14	products of other manufacturers, do you count	
15	that claim as a valid claim against Grace?	
16	A. I would need to see all the	
17	case-specific information and evaluate the	
18	case.	
19	Q. What if there was no other information	
20	than the information I've given you?	
21	MS. HARDING: I'm going to object to	
22	form and incomplete hypothetical.	
23	THE WITNESS: I doubt seriously that	
24	that would be the only information that would be	
25	available.	

FINAL - November 2, 2007 Elizabeth Anderson, Ph.D.

		Page 309
1	range of eight-hour TWAs that Dr. Lees	
2	calculated rather than the mean of the average	
3	eight-hour TWA that Mr. Lees calculated	
4	MS. HARDING: Object to form.	
5	BY MR. RASMUSSEN:	
6	Q isn't that true?	
7	A. I've already said that no credible	
8	scientist engaged in risk assessment on any	
9	circumstance for a 45-year lifespan eight hours	
10	a day for every day they worked for 45 years	
11	would pick the fact that that person is always	
12	going to be exposed to some extraordinary	
13	circumstance that differs from the mean over	
14	that period of time.	
15	And for each of these products I've	
16	chosen the highest, not the lowest, not the	
17	mean, I've chosen the highest value for the	
18	product that had the highest value to make these	
19	calculations.	
20	So that's not a credible circumstance.	
21	Q. But you didn't	
22	MS. HARDING: You know, just before we	
23	go on, I just I think we're approaching the	
24	seven hours, so we only we took a	
25	35-minute lunch. We've taken a few breaks. I	